Foznol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Foznol

Property Description
Active Ingredient Lanthanum Carbonate (La2(CO3)3)
Form Primarily Chewable Tablets
Pharmacological Class Phosphate Binder, Renal Therapeutic Agent
General Purpose To manage serum phosphate levels in chronic kidney disease
Differentiating Feature Non-calcium, non-polymer based compound

What Type of Medicine is Foznol (Lanthanum Carbonate)?

Foznol is a trademarked, prescription-only medication officially classified as a Phosphate Binder and a Renal Therapeutic Agent. Its active ingredient is Lanthanum Carbonate (La2(CO3)3), an inorganic salt compound. This drug is clinically recognized for its efficacy in managing specific mineral imbalances that arise when severe kidney impairment prevents the body from naturally filtering excess phosphate.

Foznol is distinctive as a non-calcium, non-polymer-based compound, representing a specific therapeutic alternative to older agents that contained calcium or polymer structures. Its composition involves the lanthanide element and is a synthetic compound.

Composition and Available Forms

The active substance, Lanthanum Carbonate, is supplied for Oral Administration. It is primarily available as Chewable Tablets, a format that is a key differentiating feature of the Foznol brand. The drug may also be available as a Powder for Oral Suspension.

This specific preparation ensures the medicine is readily and fully available in the digestive tract simultaneously with food. This immediate presence is essential for optimizing the drug's core function, which is to bind to dietary phosphate before it can be absorbed by the body.

General Purpose and Action Summary

The general purpose of Foznol is to help adult patients with chronic kidney disease maintain healthier serum phosphate levels when their kidneys are unable to do so naturally. Its action as a powerful chelating agent takes place entirely within the gastrointestinal tract.

Once consumed, the medicine releases lanthanum ions which immediately react with dietary phosphate to create an insoluble, inert compound. By preventing the absorption of phosphate in this manner, the drug ensures that the phosphate is excreted naturally, supporting the patient's mineral balance.

Regulatory References

  1. Lanthanum: MedlinePlus Drug Information

What side effects are possible with Foznol?

Foznol (lanthanum carbonate) is associated with adverse reactions that are predominantly gastrointestinal in nature, affecting the digestive system. These events are generally lessened by ensuring the tablet is taken with or immediately after food.

Adverse Reactions Summary

Frequency Examples of Adverse Reactions (System-Organ Class)
Very Common ( > 1 in 10) Nausea, vomiting, diarrhea, abdominal pain, headache, itching, rash
Common (up to 1 in 10) Heartburn, flatulence, hypocalcaemia (low blood calcium)
Uncommon (up to 1 in 100) Intestinal obstruction (ileus, subileus), dyspepsia, dizziness, vertigo, fatigue, increases in certain liver enzymes

Serious Safety Considerations

Serious gastrointestinal complications have been reported, including intestinal perforation (a rare event, affecting up to 1 in 1,000 people) and intestinal obstruction (uncommon). These risks are mitigated by the mandatory instruction to chew the tablets completely; swallowing tablets whole or incompletely chewed has been associated with these serious adverse events.

Restrictions and Limitations

Foznol is contraindicated in patients with pre-existing bowel obstruction, ileus, fecal impaction, or hypophosphataemia (low phosphate levels). Caution is required in patients predisposed to bowel obstruction, such as those with a history of abdominal surgery or peritonitis. It is not recommended for use during pregnancy or breast-feeding, and safety has not been established in the pediatric population (under 18 years of age).

Foznol has radio-opaque properties and may appear as an imaging agent on abdominal X-rays.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Lanthanum Carbonate establishes the documented clinical presentation and the required emergency actions for overdosage.

Documented Overdose Presentation

In cases of a suspected Lanthanum Carbonate overdosage, the manifestations officially described are typically common adverse reactions, including headache, nausea, and vomiting. These symptoms are largely associated with the drug’s primary action, which is topical and confined to the gastrointestinal tract. Regulatory data confirms the compound has a minimal potential for acute systemic toxicity, with high-dose evaluations in healthy adults and animal studies reporting no deaths or severe acute adverse effects.

Regulator-Mandated Emergency Actions

The management approach is guided by the fact that Lanthanum Carbonate is minimally absorbed, and the majority of the substance is excreted in the feces. Due to this localized action, the official regulatory guidance for overdosage specifies that supportive therapy is recommended.

Authorities mandate that for the proper clinical management of a suspected drug overdose, a regional poison control centre must be contacted immediately. It is also noted that the regulatory documents do not mention or specify a known antidote for Lanthanum Carbonate overdosage.

Therapeutic Uses of Foznol

What Foznol Treats: Main Uses and Benefits

Foznol is indicated for use in managing elevated serum phosphate levels in adult patients with end-stage renal disease (ESRD).

Foznol is commonly used for managing hyperphosphatemia, a condition involving sustained elevation of serum phosphorus associated with advanced Chronic Kidney Disease (CKD). It provides a necessary therapeutic benefit by contributing to the management of this mineral imbalance, which is generally considered relevant when dietary restrictions alone are insufficient and for patients on maintenance dialysis.


The primary therapeutic role is in managing the ongoing manifestations related to phosphate overload, particularly those involving CKD-Mineral and Bone Disorder (CKD-MBD). By managing phosphate levels, the medication may assist with supporting bone health and contributes to maintaining general well-being.

This medicine is commonly integrated into the treatment plan for adult patients undergoing haemodialysis or peritoneal dialysis for managing the phosphate introduced through daily food intake. Indications include managing elevated serum phosphorus, supporting bone health, and assisting with controlling mineral deposits.

“This continuous management provides supportive relief and helps patients cope more steadily with the manifestations of this chronic condition.”

Quick Fact: Relief for Mineral Imbalance
This therapy supports general well-being by managing the chronic, unseen systemic mineral overload relevant in contexts involving functional stress on cardiovascular and bone systems.

Eligibility and Restrictions for Use

Who Can and Cannot Use Foznol?

Foznol (Lanthanum Carbonate) is approved by regulatory bodies for specific patient groups and is prohibited or restricted in others based on official labeling.

Approved and Contraindicated Populations

Category Regulatory Status/Statement
Approved Population Adults (18 years and older) with End-Stage Renal Disease (ESRD), including those on maintenance dialysis [FDA, Health Canada].
Absolute Contraindications Patients with current bowel obstruction (e.g., ileus) or fecal impaction. Patients with established hypophosphatemia [Health Canada].

Restricted or Not Recommended Use

Foznol is not recommended for pediatric patients (under 18 years), as safety and efficacy in children and adolescents have not been established. The medicine is also not recommended for women who are pregnant or breastfeeding due to insufficient human data. Use requires caution in patients with an altered gastrointestinal anatomy or hypomotility disorders, as these conditions may predispose the patient to severe gastrointestinal complications. Additionally, safety and efficacy have not been established in patients with active inflammatory bowel diseases such as Crohn's disease or ulcerative colitis [EMA, FDA].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Foznol (Lanthanum Carbonate) has a low potential for systemic drug interactions because of its very low systemic absorption. The official interaction profile is dominated by a pharmacokinetic interaction due to the drug's action as a chelating agent within the gastrointestinal tract, which results in reduced absorption/bioavailability of co-administered oral medicines. Lanthanum is not a substrate or inhibitor of major CYP450 enzyme groups (e.g., CYP1A2, CYP2D6, CYP3A4).

Clinically Significant Exposure-Altering Interactions

These substances require specific timing separation as their systemic exposure is significantly reduced when taken simultaneously:

  • Oral Quinolone Antibiotics (e.g., ciprofloxacin) require administration at least 1 hour before or 4 hours after Foznol.
  • Thyroid Hormone Replacement Therapy (e.g., levothyroxine) should not be taken within 2 hours of dosing with Foznol. A reduction in T4 concentration by approximately 40% has been observed.

Other Interactions and Restrictions

Category Official Regulatory Documentation Entity
Substance Class Other oral drugs that bind to Cationic Antacids (e.g., tetracyclines, certain ACE-inhibitors) require administration separation.
Vitamins and Supplements Lanthanum Carbonate is documented to not affect serum levels of fat-soluble vitamins (A, D, E, K) or Vitamin B12. Co-administration with citrate salts does not affect lanthanum absorption.
Population-Specific Note In patients with conditions leading to a marked reduction of bile flow, caution is advised due to the potential for slower lanthanum elimination and increased tissue deposition.

Mechanism of Action

Chemical Sequestration of Dietary Phosphate

The mechanism of Foznol is a physicochemical binding process entirely confined to the gastrointestinal tract, functioning to sequester minerals before they are absorbed. The core action involves the trivalent lanthanum cation (La^3+) which is released into the gut lumen. This cation acts as a chelating agent, binding with high affinity to the phosphate anion ( PO4^3-) liberated from food during digestion. This non-enzymatic cation binding forms the insoluble compound lanthanum phosphate (La PO4).

Interruption of Intestinal Absorption Pathway

By forming the highly insoluble lanthanum phosphate complex, the mechanism functionally interrupts the intestinal phosphate absorption pathway. Since the complex cannot be dissolved or traverse the epithelial barrier, the phosphate is sequestered within the gut and eliminated naturally via fecal excretion. This cascade produces the measurable physiological effect of reducing the total net phosphate load entering the systemic circulation, resulting in a decrease in plasma phosphate concentration.

Constraint of Co-presence Dependence

The entire mechanism is fundamentally constrained by co-presence dependence—the La^3+ must be present simultaneously with the dietary phosphate to facilitate binding. The binding mechanism is strictly limited to phosphate in the gut; it does not affect phosphate already circulating in the bloodstream.

Dosage and Administration Information

How to Use Foznol

Foznol (lanthanum carbonate) is administered exclusively via the oral route as a long-term therapy for the management of chronic hyperphosphatemia. The available forms include chewable tablets (500 mg to 1,000 mg) and an oral powder.


Dosing and Administration Frequency

The medicine's usage pattern is intrinsically linked to food intake. The total daily dose must be divided and taken with or immediately after meals. This ensures the active substance is present to bind to dietary phosphate.

The usual initial total daily dose for adults is 1,500 mg, which is then adjusted over time. Dose modifications are typically made in increments of 750 mg per day every two to three weeks, based on serum phosphate levels, with doses generally ranging from 1,500 mg to 3,000 mg per day.


Administration Instructions

Proper preparation is essential for Foznol to function correctly. Chewable tablets must be chewed or crushed completely before swallowing; they are not to be swallowed whole.

The oral powder must be mixed with a small amount of soft food, such as applesauce, and consumed immediately.

For adults who miss a scheduled dose, the recommendation is generally to omit the missed dose and take the next dose with the next scheduled meal. Additionally, to maintain the effectiveness of other medications, Foznol administration must be separated by a specific time interval (e.g., one to four hours) from certain other oral drugs, such as quinolone antibiotics. The safety and efficacy of Foznol have not been established for use in pediatric patients under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Foznol (Lanthanum Carbonate)


Evidence for Use in Managing High Phosphate Levels in ESRD

The main body of clinical evidence for Foznol was studied for its effects on elevated phosphate levels (hyperphosphatemia) in adult patients with End-Stage Renal Disease (ESRD) who are receiving maintenance dialysis. Research primarily included short-term, randomized controlled trials (RCTs), where some studies compared Foznol to an inactive substance or to other standard phosphate-binding medicines. Researchers focused on measurements of the change in serum phosphorus levels.

Studies reported that measurements of serum phosphate levels changed in the observed populations following administration. Further research, including large comparative trials, was observed in studies monitoring phosphate levels over longer periods. These data show patterns related to the maintenance of the measured biomarker throughout the research period.


Research Focus on Mineral and Bone Disorder (CKD-MBD) Markers

Research also examined the patterns of systemic or functional imbalance associated with chronic kidney disease, particularly how Foznol was evaluated in relation to CKD-MBD. These studies often took the form of active comparator trials that specifically evaluated Foznol against older treatments, such as calcium-containing phosphate binders. Outcomes linked to mineral metabolism, specifically the occurrence of hypercalcemia (high serum calcium levels), was evaluated in these comparator studies.

Comparative studies described patterns related to the measured incidence of hypercalcemia, which differed between the Foznol population and the populations receiving calcium-based phosphate binders. However, the evidence relating to final skeletal hard outcomes, such as definitive fracture risk reduction across all comparative treatments, is limited. The specialized nature of these studies means that sample sizes were modest.


Key Limitations and Areas of Uncertainty in the Research

Research on Foznol includes multiple studies evaluating the primary biomarker outcome. However, there are significant gaps where certainty remains low regarding long-term, patient-centered outcomes. Comparative evidence is lacking for definitive conclusions regarding whether Foznol may show evidence of a differential effect on patient survival or cardiovascular health compared against all other non-calcium-containing binders. The research does not determine whether an individual will respond similarly to the group findings.

Frequently Asked Questions (FAQ)

Common questions about Foznol (FAQ)

Q: How quickly should I expect to feel the effects of Foznol?

A: Foznol is designed to start working immediately in the gut by binding to phosphate from food. The actual therapeutic goal—a measurable reduction in the amount of phosphate in your blood—is monitored through laboratory measurements. Dosage changes are guided by your healthcare provider's review of these results.


Q: Are there any common but mild side effects of taking Foznol?

A: According to official product information, the most common side effects are usually related to the digestive system and include nausea, vomiting, diarrhea, abdominal pain, headache, itching, and rash. These very common reactions, which affect more than 1 in 10 people, are sometimes managed or monitored by a healthcare professional.


Q: Can taking Foznol cause problems with my stomach?

A: Yes, problems with the stomach and digestive tract are the most frequently reported adverse reactions, according to regulatory documents. These include common issues like nausea, diarrhea, heartburn, and flatulence. The product information notes that severe gastrointestinal issues, including intestinal obstruction or perforation, have been reported rarely and require immediate medical attention.


Q: Is it normal to feel a little tired when first starting Foznol?

A: Feeling tired or fatigue is listed in official product information as an uncommon side effect, meaning it may affect up to 1 in 100 people. It is not listed among the most common reactions reported when beginning this medication.


Q: How long does Foznol stay in your system after stopping it?

A: Foznol is mainly designed to work inside the digestive tract, and systemic absorption is minimal. The small amount that does enter the body has an elimination half-life of about 53 hours in patients receiving dialysis. Most of the medication is naturally passed out of the body through the feces.


Q: Are there any vitamins or supplements I should avoid while on Foznol?

A: Official studies indicate that Foznol does not affect the absorption of fat-soluble Vitamins A, D, E, and K or Vitamin B12. However, because Foznol acts as a chelating agent in the gut, there is a recognized potential for reduced bioavailability of other concurrently administered oral drugs or supplements that bind to cations.


Q: Can Foznol affect the results of lab tests?

A: Yes, Foznol contains an element that is radio-opaque. Official safety information notes that this can cause the medication to appear as an imaging agent on abdominal X-rays or CT scans, which may interfere with the interpretation of those images.


Q: Can older adults safely use Foznol?

A: Regulatory labeling indicates that Foznol is approved for adults and that no dose adjustment is necessary for geriatric patients. Treatment is initiated and monitored according to the standard adult protocol.


Q: Is it safe to drive or operate machinery while taking Foznol?

A: Dizziness and vertigo (a spinning sensation) are uncommon side effects reported with Foznol. If these effects are experienced, official labeling advises that they may impair an individual's ability to drive or safely use machinery.


Q: How does Foznol affect the liver or kidneys?

A: Lanthanum is minimally absorbed systemically, and its primary elimination pathway is through the feces. Increases in certain liver enzymes have been reported as an uncommon adverse reaction. Regulatory guidance advises caution for patients with existing liver impairment or reduced bile flow.


Q: Are there any pre-existing conditions that prevent someone from taking Foznol?

A: Yes, Foznol is contraindicated (must not be used) in patients with bowel obstruction, severe constipation, or very low phosphate levels (hypophosphatemia). Regulatory guidance advises caution for individuals with an altered gastrointestinal anatomy, hypomotility disorders, or a history of inflammatory bowel diseases.


Q: Can taking Foznol impact fertility?

A: Non-clinical (animal) studies at doses higher than the maximum recommended human dose found no effect on fertility or mating parameters. The full impact on human fertility is limited.


Q: What are the signs of a serious allergic reaction to Foznol?

A: Post-marketing safety surveillance has included reports of allergic skin reactions, such as hives. The labeling notes that if signs of a severe allergic reaction (such as swelling of the face, throat, or difficulty breathing) occur, immediate medical evaluation is necessary.


Q: What is the recommended advice for patients if they experience an unexpected symptom while on Foznol?

A: Official patient information recommends that individuals contact a healthcare professional immediately if they develop symptoms of severe constipation or severe stomach cramps. Patients should report any unexpected symptoms to their prescribing physician.


Q: Is Foznol considered a new type of drug?

A: The active ingredient, lanthanum carbonate, was approved in the mid-2000s in the US and Europe. It is categorized as a non-calcium, non-polymer-based phosphate binder, which distinguishes it from older classes of medication used for the same purpose.


Q: Does Foznol have a generic version available yet?

A: Yes, a generic version of the active ingredient, lanthanum carbonate, is available for the original chewable tablet form, according to regulatory listings.


Q: Does Foznol need to be stored in the refrigerator?

A: No, official storage guidelines specify that Foznol must be stored at room temperature, typically around 25 extdegreeC or 77 extdegreeF. It must be protected from light and moisture, and it is mandatory to keep it from freezing.


Q: What is the typical duration of treatment with Foznol?

A: Foznol is intended for long-term therapy to manage chronic hyperphosphatemia. Patients in clinical studies were treated for up to 4.5 years, though it is used for as long as medically necessary based on the individual's condition.


Q: What should I do if I accidentally take two doses of Foznol close together?

A: Official patient information recommends contacting a poison control center or seeking emergency medical care if there is suspicion of having taken too much of this medication.


Q: Could Foznol be the reason I'm experiencing headaches?

A: Yes, regulatory documents list headaches as a very common side effect associated with Foznol. This means that headaches are among the effects reported by more than 1 in 10 people during clinical studies.


Q: Does Foznol interact with oral contraceptives?

A: Studies specifically examining an interaction between Foznol and oral contraceptives were not conducted. However, the potential for Foznol to reduce the absorption of other oral medications in the gut exists, and specific separation in dosing is required for certain other drug classes.


Q: Is it okay to take Foznol with a glass of milk?

A: Foznol is instructed to be taken with or immediately after meals to work properly. Official administration instructions specify mixing the oral powder with a small amount of soft food, such as applesauce. The chewable tablets must be chewed completely and swallowed with a meal.


Q: Do I need a special prescription for Foznol?

A: Foznol is classified as a prescription-only medication by regulatory authorities and is not available over-the-counter. It is not currently categorized as a controlled substance by the US Drug Enforcement Administration (DEA).

How should Foznol be stored and disposed of?

How to Store and Dispose of Foznol?

The official storage and disposal requirements for Foznol (Lanthanum Carbonate) are defined by regulatory labeling to protect the medication's stability and ensure patient safety.

Official Storage Conditions

Storage Component Requirement
Temperature Store at room temperature and keep from freezing.
Protection Must be stored in the original package and in a closed container to protect the tablets from light and moisture.
Safety It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Rules

Do not use Foznol after its labeled expiry date. Unused or expired medication must not be disposed of via household waste or wastewater. Instead, disposal must follow official local regulations, and patients are instructed to consult a pharmacist or healthcare professional for guidance on proper throw-away procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Foznol found in:

A-Z Index: